Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation

Acta Pharmacologica Sinica

Volumn 32, Issue 7, 2011, Pages 879-887

  Fu, Yong Nan ^a   Xiao, Han ^a   Ma, Xiao Wei ^a   Jiang, Sheng Yang ^a   Xu, Ming ^a   Zhang, You Yi ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Akt protein kinase B; AMP activated protein kinase; cardiac hypertrophy; mammalian target of rapamycin; metformin; protein synthesis; transverse aortic constriction

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; ATTENUATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART LEFT VENTRICLE OVERLOAD; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; MALE; MOUSE; NONHUMAN; WESTERN BLOTTING; WILD TYPE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOMEGALY; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; HEART; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; PHOSPHORYLATION;

EID: 79960046907     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.229     Document Type: Article

References (35)

1. Ef fect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
3. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinasedevelopment of the energy sensor concept. J Physiol 2006; 574: 7-15. (Pubitemid 43905792)
4. Li YJ, Wang PH, Chen C, Zou MH, Wang DW. Improvement of mechanical heart function by trimetazidine in db/db mice. Acta Pharmacol Sin 2010; 31: 560-9.
5. Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res 2007; 100: 474-88. (Pubitemid 46673257)
6. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74. (Pubitemid 32995375)
7. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009; 104: 403-11.
8. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, et al. Metformin prevents progression of heart failure in dogs: role of AMPactivated protein kinase. Circulation 2009; 119: 2568-77.
9. Lorell BH. Transition from hypertrophy to failure. Circulation 1997; 96: 3824-7. (Pubitemid 27506035)
10. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79. (Pubitemid 38249147)
11. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol Genomics 2004; 16: 349-60. (Pubitemid 38420055)
12. Wang J, Xu N, Feng X, Hou N, Zhang J, Cheng X, et al. Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res 2005; 97: 821-8. (Pubitemid 41447133)
13. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. Activation of AMPactivated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004; 279: 32771-9. (Pubitemid 39014736)
14. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-52. (Pubitemid 47105521)
15. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG 4th, Schlattner U, et al. Activation of the AMP-activated protein kinase by the antidiabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004; 279: 43940-51. (Pubitemid 39390702)
16. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, et al. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006; 130: 2099-112. (Pubitemid 43816952)
17. Snorgaard O, Kober L, Carlsen J. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Intern Med 1997; 242: 407-12. (Pubitemid 27513107)
18. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFβ1-Smad3 signalling pathway. Cardiovasc Res 2010; 87: 504-13.
19. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, et al. Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1. Am J Physiol Heart Circ Physiol 2002; 283: H1253-62.
20. Schultz JJ, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, et al. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109: 787-96. (Pubitemid 34263155)
21. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130-5. (Pubitemid 34747453)
22. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, et al. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004; 43: 499-503. (Pubitemid 38174161)
23. Tian R, Musi N, DAgostino J, Hirshman MF, Goodyear LJ. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001; 104: 1664-9. (Pubitemid 32947531)
24. Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B, et al. AMP activated protein kinase-α2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008; 52: 918-24.
25. Stuck BJ, Lenski M, Bohm M, Laufs U. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem 2008; 283: 32562-9.
26. Lei B, Chess DJ, Keung W, OShea KM, Lopaschuk GD, Stanley WC. Transient activation of p38 MAP kinase and up-regulation of Pim-1 kinase in cardiac hypertrophy despite no activation of AMPK. J Mol Cell Cardiol 2008; 45: 404-10.
27. Zarrinpashneh E, Beauloye C, Ginion A, Pouleur AC, Havaux X, Hue L, et al. AMPKα2 counteracts the development of cardiac hypertrophy induced by isoproterenol. Biochem Biophys Res Commun 2008; 376: 677-81.
28. Xing Y, Musi N, Fujii N, Zou L, Luptak I, Hirshman MF, et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative α2 subunit of AMP-activated protein kinase. J Biol Chem 2003; 278: 28372-7. (Pubitemid 36935737)
29. Russell RR 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495-503. (Pubitemid 39572099)
30. Yang J, Holman GD. Insulin and contraction stimulate exocytosis, but increased AMP-activated protein kinase activity resulting from oxidative metabolism stress slows endocytosis of GLUT4 in cardiomyocytes. J Biol Chem 2005; 280: 4070-8. (Pubitemid 40288570)
31. DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Courtois M, et al. Akt1 is required for physiological cardiac growth. Circulation 2006; 113: 2097-104.
32. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7: 589-600. (Pubitemid 44325350)
33. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004; 109: 3050-5. (Pubitemid 38808328)
34. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-12. (Pubitemid 350145909)
35. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7. (Pubitemid 34579158)